Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2016 May 19;127(20):2427-38.
doi: 10.1182/blood-2015-11-679639. Epub 2016 Feb 16.

Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis

Pierre Teira  1 , Minoo Battiwalla  2 , Muthalagu Ramanathan  3 , A John Barrett  2 , Kwang Woo Ahn  4 , Min Chen  5 , Jaime S Green  6 , Ayman Saad  7 , Joseph H Antin  8 , Bipin N Savani  9 , Hillard M Lazarus  10 , Matthew Seftel  11 , Wael Saber  5 , David Marks  12 , Mahmoud Aljurf  13 , Maxim Norkin  14 , John R Wingard  14 , Caroline A Lindemans  15 , Michael Boeckh  16 , Marcie L Riches  17 , Jeffery J Auletta  18
Affiliations
Comment

Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis

Pierre Teira et al. Blood. .

Abstract

Single-center studies have reported an association between early (before day 100) cytomegalovirus (CMV) reactivation and decreased incidence of relapse for acute myeloid leukemia (AML) following allogeneic hematopoietic cell transplantation. To substantiate these preliminary findings, the Center for International Blood and Marrow Transplant Research (CIBMTR) Database was interrogated to analyze the impact of CMV reactivation on hematologic disease relapse in the current era. Data from 9469 patients transplanted with bone marrow or peripheral blood between 2003 and 2010 were analyzed according to 4 disease categories: AML (n = 5310); acute lymphoblastic leukemia (ALL, n = 1883); chronic myeloid leukemia (CML, n = 1079); and myelodysplastic syndrome (MDS, n = 1197). Median time to initial CMV reactivation was 41 days (range, 1-362 days). CMV reactivation had no preventive effect on hematologic disease relapse irrespective of diagnosis. Moreover, CMV reactivation was associated with higher nonrelapse mortality [relative risk [RR] among disease categories ranged from 1.61 to 1.95 and P values from .0002 to <.0001; 95% confidence interval [CI], 1.14-2.61). As a result, CMV reactivation was associated with lower overall survival for AML (RR = 1.27; 95% CI, 1.17-1.38; P <.0001), ALL (RR = 1.46; 95% CI, 1.25-1.71; P <.0001), CML (RR = 1.49; 95% CI, 1.19-1.88; P = .0005), and MDS (RR = 1.31; 95% CI, 1.09-1.57; P = .003). In conclusion, CMV reactivation continues to remain a risk factor for poor posttransplant outcomes and does not seem to confer protection against hematologic disease relapse.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Cumulative incidence curves for CMV reactivation according to D/R serology.
Figure 2
Figure 2
Cumulative incidence curves for indicated hematologic disease relapse according to D/R CMV serology.
Figure 3
Figure 3
Multivariable analysis of risk factors for outcomes depending on CMV donor/recipient serology or CMV reactivation. (A) Relapse, (B) NRM, (C) aGVHD, (D) cGVHD, (E) DFS, and (F) OS. For multivariate analysis, D−/R− = 1, and no CMV reactivation = 1.
Figure 4
Figure 4
Cumulative incidence curves for NRM by indicated hematologic disease and according to D/R CMV serology.
See this image and copyright information in PMC

Comment in

  • CMV: persistent nemesis for SCT.
    Feuchtinger T. Feuchtinger T. Blood. 2016 May 19;127(20):2368-9. doi: 10.1182/blood-2016-03-701672. Blood. 2016. PMID: 27207320 No abstract available.

Comment on

References

    1. Ariza-Heredia EJ, Nesher L, Chemaly RF. Cytomegalovirus diseases after hematopoietic stem cell transplantation: a mini-review. Cancer Lett. 2014;342(1):1–8. - PubMed
    1. Ljungman P, Hakki M, Boeckh M. Cytomegalovirus in hematopoietic stem cell transplant recipients. Hematol Oncol Clin North Am. 2011;25(1):151–169. - PMC - PubMed
    1. Ozdemir E, Saliba RM, Champlin RE, et al. Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies. Bone Marrow Transplant. 2007;40(2):125–136. - PubMed
    1. Einsele H, Steidle M, Vallbracht A, Saal JG, Ehninger G, Müller CA. Early occurrence of human cytomegalovirus infection after bone marrow transplantation as demonstrated by the polymerase chain reaction technique. Blood. 1991;77(5):1104–1110. - PubMed
    1. Osarogiagbon RU, Defor TE, Weisdorf MA, Erice A, Weisdorf DJ. CMV antigenemia following bone marrow transplantation: risk factors and outcomes. Biol Blood Marrow Transplant. 2000;6(3) 280-8. - PubMed

Publication types

MeSH terms